Chronic hyperbaric exposure activates proinflammatory mediators in humans

Journal of Applied Physiology

Volumn 92, Issue 6, 2002, Pages 2375-2380

  Ersson, Anders ^a,b   Walles, Maria ^a,b   Ohlsson, Kjell ^a,b   Ekholm, Anders ^a,b,c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c Ringerike Sykehus   (Norway)

Author keywords

Decompression; Diving; Inflammatory activation

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; INTERLEUKIN 8; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALCIN; PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; DECOMPRESSION SICKNESS; DIVER; DIVING; HUMAN; HYPERBARISM; INFLAMMATION; LEUKOCYTE ACTIVATION; MALE; MEDIATOR RELEASE; PRIORITY JOURNAL; SOLDIER;

EID: 0036082172     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/japplphysiol.00705.2001     Document Type: Article

References (56)

1. IL 1 receptor antagonist
2. Studies of the release and turnover of a human neutrophil lipocalcin
3. Variability over time of complement activation induced by air bubbles in human and rabbit sera
4. A sandwich enzyme immunoassay for the determination of neutrophil lipocalin in body fluids
5. Decompression induced venous gas emboli in sport diving: Detection with 2D echocardiography and pulsed Doppler
6. Venous gas embolism: Detection with pulsed Doppler guided two dimensional echocardiography
7. Activation of coagulation in decompression illness
8. Immune function in hyperbaric environments, diving, and decompression
9. Cardiopulmonary changes with moderate decompression in rats
10. Venous gas embolism: Time course of residual pulmonary intravascular bubbles
11. Transesophageal echocardiographic study of decompression-induced venous induced gas emboli
12. Decompression sickness during construction of the Dartford tunnel
13. Neutrophil activating factor (NAF) induces polymorphonuclear leukocyte adherence to endothelial cells and to subendothelial matrix proteins
14. Cytokines as mediators in the pathogenesis of septic shock
15. Secretory leukocyte protease inhibitor interferes with uptake of lipopolysaccaride by macrophages
16. Leukocyte activation in atherosclerosis: Correlation with risk factors
17. Cytokine response after acute hyperbaric exposure in the rat
18. Pathogenesis of decompression disorders
19. Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia
20. Increased plasma levels of interleukin-6 in sepsis
21. The endothelium in sepsis: Source of and target for inflammation
22. Uber einen hormonabhangigen inhibitor für proteolytische enzyme in mannlichen accessorischen geschlechtsdrusen und im sperma
23. Antibacterial activity of antileukoprotease
24. Microbubble damage to the bloodbrain barrier: Relevance to decompression sickness
25. Complement activation in divers after repeated air/heliox dives and its possible relevance to DCI
26. The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1β production in human monocytes and neutrophils
27. Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage derived lipopolysaccharide inhibitor
28. Secretory leukocyte protease inhibitor: A macrophage product induced by and antagonistic to bacterial lipopolysaccharide
29. Extracorporeal circulation causes release of neutrophil gelatinase-associated lipocalin (NGAL)
30. Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1 mediated event
31. Hypoxic induction of interleukin-8 gene expression in human endothelial cells
32. Interleukin-8 and monocyte chemotactic activating factor responses to cardiopulmonary bypass
33. Lower decompression sickness risk in rats by intravenous injection of foreign protein
34. Different patterns of local and systemic release of proinflammatory and anti-inflammatory mediators in severely injured patients with chest trauma
35. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase
36. Secretory leukocyte protease inhibitor in mice regulates local and remote organ inflammatory injury induced by hepatic ischemia/reperfusion
37. Increased nitric oxide in expired air in patients with Sjogren's syndrome. BHR study group. Bronchial hyperresponsiveness
38. Secretory leukocyte protease inhibitor: A human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro
39. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription
40. Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor
41. Induction by transforming growth factor-β1 of the interleukin- 1 receptor antagonist and of its intracellular form in human polymorphonuclear cells
42. Doppler and ultrasonic bubble detection
43. Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality
44. Mediators in polytrauma-pathophysiological significance and clinical relevance
45. Effects of secretory leukocyte protease inhibitor on the production of the anti-inflammatory cytokines, IL-10 and transforming growth factor-beta (TGF-β), by lipopolysaccharide-stimulated macrophages
46. Attenuation of cardiopulmonary bypass derived inflammatory reduction reduces myocardial reperfusion injury in cardiac operations
47. Cytokine-induced neutrophil-derived interleukin- 8
48. Comparative analysis of decompression sickness: Type and time of onset
49. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin-6, interleukin- 1, and fatal outcome
50. Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1
51. Identification of individuals susceptible to decompression sickness
52. Relation between complement activation and susceptibility to decompression sickness
53. Tissue destruction by neutrophils
54. Identification of SLPI (secretory leukocyte protease inhibitor) in human mast cells using immunohistochemistry and in situ hybridisation
55. Lipocalins as biochemical markers of disease
56. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteases